FDA approves new IV antibacterial drug used to treat adults with skin infections
May 27th 2014FDA has approved dalbavancin (Dalvance, Durata Therapeutics) for injection for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Read More
Investigational drug in phase 3 study has potential to be first DMARD for knee osteoarthritis
May 27th 2014With global disability concerns rising, Voltarra Pharmaceuticals, Inc. and Menzies Research Institute at the University of Tasmania in Hobart, Australia, have initiated a phase 3, randomized multicenter clinical trial to assess the efficacy and safety of VOLT01 for controlling knee osteoarthritis (OA).
Read More
Botulinum toxin injection may ward off postop AFib
May 24th 2014Injecting botulinum toxin injection into the epicardial fat pads prevented recurrences of atrial tachyarrhythmia in the postoperative period in patients with prior paroxysmal atrial fibrillation (PAF) undergoing coronary artery bypass grafting (CABG) surgery, according to results of a study presented at the Heart Rhythm Society meeting in San Francisco.
Read More
Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have the most common epidermal growth factor receptor (EGFR) mutation (exon 19 deletion) lived longer if treated with first-line afatinib (Gilotrif) compared to chemotherapy, according to data presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), in Chicago.
Read More
Pirfenidone reduces disease progression of IPF
May 23rd 2014Pirfenidone (Esbriet), an oral antifibrotic therapy, was able to reduce progression of idiopathic pulmonary fibrosis (IPF) and reduce the risk of mortality, according to phase 3 trial results presented at the American Thoracic Society International Conference in San Diego.
Read More
Fixed-dose combination shows improved lung function in COPD patients: Study
May 22nd 2014The fixed-dose combination of tiotropium and olodaterol (T+O FDC) has the potential to become a viable once-daily chronic obstructive pulmonary disease (COPD) treatment, according to data presented at the 2014 American Thoracic Society (ATS) International Conference, in San Diego.
Read More
Clinicians should not start or continue statins in patients with sepsis-associated acute respiratory distress syndrome (ARDS), according to a study published in the May 18, 2014, New England Journal of Medicine, along with accompanying editorials evaluating the research’s goals and outcomes.
Read More
Investigational TKI nintedanib slowed lung function loss in idiopathic pulmonary fibrosis
May 21st 2014Nintedanib, an investigational small molecule tyrosine kinase inhibitor (TKI), slowed lung function loss in patients with idiopathic pulmonary fibrosis (IPF), according to the results of 2 pivotal phase 3 trials presented at the American Thoracic Society International Conference in San Diego.
Read More
Precision system "prints" individualized med dosages for patients
May 19th 2014A mathematical model to predict-and a portable inkjet technology to produce-exact medication dosages tailored for specific patients, an advance in personalized medicine that could improve drug effectiveness and reduce adverse reactions, has been created by Purdue University researchers.
Read More
Shortage of IV metronidazole antibiotic prompts indication-specific alternatives
May 16th 2014There has been a recent national backorder of iv Metronidazole (Flagyl) due to manufacturing delays with Hospira. As a result of this delay Hospira has not been able to provide a tentative timeline or estimate date of when IV metronidazole will be available to purchasers/buyers once again. While this situation plays out, there are general management strategies that might be implemented based on the facility.
Read More
CDC releases guidelines for HIV preventive meds
May 16th 2014The Centers for Disease Control and Prevention (CDC) released a new set of comprehensive guidelines that recommends that physicians should consider prescribing antiretroviral medication to individuals who are not infected with HIV but are at high risk of infection.
Read More
Meds for alcohol use disorders effective, but underutilized
May 15th 2014Several medications can help people with alcohol use disorders to maintain abstinence or to reduce drinking, when added to psychosocial interventions. Two drugs, acamprosate and oral naltrexone, have the best evidence supporting their benefits, according to an analysis of more than 100 studies examining the use of medications to treat these conditions.
Read More
Drugs in Perspective: Sovaldi (sofosbuvir)
May 15th 2014Hepatitis C is a viral disease that causes the inflammation of the liver which can ultimately lead to a diminished liver function or liver failure. The majority of individuals who are infected with HCV do not present with any symptoms of the disease until the appearance of liver damage. According to the Centers for Disease Control and Prevention it is estimated that approximately 3.2 million American are infected with hepatitis C and globally about 150 million people have hepatitis C. Up to 85% of those who are initially infected with HCV will not eliminate the virus and become chronically infected.
Read More
Eliminating med copays after heart attack can improve outcomes for non-white patients
May 14th 2014Eliminating copays for preventive medications prescribed for post-heart attack patients can significantly improve medication adherence for all patients, according to a study published in Health Affairs.
Read More
Rx errors in HIV patients can be reduced by pharmacists
May 14th 2014A pharmacist who is proficient at monitoring and ensuring appropriate therapy, as well as providing necessary medication counseling, will greatly enhance compliance and reduce potential adverse drug reactions and interactions in HIV-positive hospital patients, according to FormularyWatch advisor James M. Wooten, PharmD, associate professor, department of medicine, section of clinical pharmacology, University of Missouri-Kansas City.
Read More